Traders bought shares of Becton, Dickinson and Company (NYSE:BDX) on weakness during trading hours on Thursday. $93.42 million flowed into the stock on the tick-up and $49.64 million flowed out of the stock on the tick-down, for a money net flow of $43.78 million into the stock. Of all stocks tracked, Becton, Dickinson and had the 20th highest net in-flow for the day. Becton, Dickinson and traded down ($2.60) for the day and closed at $224.23

A number of brokerages recently issued reports on BDX. Stifel Nicolaus reiterated a “buy” rating and issued a $245.00 price objective on shares of Becton, Dickinson and in a research report on Friday, November 3rd. Morgan Stanley increased their price objective on Becton, Dickinson and from $205.00 to $245.00 and gave the stock an “equal weight” rating in a research report on Friday, November 3rd. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $230.00 price objective (up previously from $210.00) on shares of Becton, Dickinson and in a research report on Friday, November 3rd. Zacks Investment Research upgraded Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $234.00 price target on the stock in a research report on Tuesday, October 31st. Finally, Wells Fargo & Company restated a “positive” rating and set a $235.00 price target (up previously from $225.00) on shares of Becton, Dickinson and in a research report on Tuesday, October 24th. They noted that the move was a valuation call. Four analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. Becton, Dickinson and currently has a consensus rating of “Buy” and a consensus target price of $217.08.

The company has a current ratio of 5.56, a quick ratio of 5.01 and a debt-to-equity ratio of 1.48. The stock has a market capitalization of $51,618.57, a PE ratio of 23.90, a price-to-earnings-growth ratio of 1.78 and a beta of 1.04.

Becton, Dickinson and (NYSE:BDX) last released its quarterly earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.37 by $0.03. Becton, Dickinson and had a return on equity of 22.51% and a net margin of 8.52%. The business had revenue of $3.17 billion for the quarter, compared to the consensus estimate of $3.14 billion. During the same quarter last year, the business posted $2.12 earnings per share. The company’s revenue for the quarter was down 2.0% on a year-over-year basis. analysts expect that Becton, Dickinson and Company will post 10.63 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Friday, December 29th. Shareholders of record on Friday, December 8th will be given a dividend of $0.75 per share. This is an increase from Becton, Dickinson and’s previous quarterly dividend of $0.73. The ex-dividend date is Thursday, December 7th. This represents a $3.00 dividend on an annualized basis and a yield of 1.34%. Becton, Dickinson and’s dividend payout ratio (DPR) is presently 62.80%.

In other news, insider Gary M. Cohen sold 15,512 shares of the firm’s stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $203.77, for a total transaction of $3,160,880.24. Following the transaction, the insider now directly owns 95,781 shares of the company’s stock, valued at $19,517,294.37. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Stephen Sichak sold 11,787 shares of the firm’s stock in a transaction dated Friday, September 8th. The shares were sold at an average price of $200.46, for a total value of $2,362,822.02. Following the transaction, the insider now directly owns 14,038 shares in the company, valued at $2,814,057.48. The disclosure for this sale can be found here. Company insiders own 1.40% of the company’s stock.

Several large investors have recently made changes to their positions in the company. Guardian Life Insurance Co. of America grew its stake in shares of Becton, Dickinson and by 0.7% during the first quarter. Guardian Life Insurance Co. of America now owns 819 shares of the medical instruments supplier’s stock valued at $150,000 after buying an additional 6 shares during the last quarter. Family Firm Inc. grew its stake in shares of Becton, Dickinson and by 0.5% in the second quarter. Family Firm Inc. now owns 1,212 shares of the medical instruments supplier’s stock worth $236,000 after purchasing an additional 6 shares during the last quarter. Northwest Quadrant Wealth Management LLC grew its stake in shares of Becton, Dickinson and by 0.4% in the second quarter. Northwest Quadrant Wealth Management LLC now owns 1,686 shares of the medical instruments supplier’s stock worth $332,000 after purchasing an additional 6 shares during the last quarter. Wellington Shields & Co. LLC grew its stake in shares of Becton, Dickinson and by 0.3% in the second quarter. Wellington Shields & Co. LLC now owns 2,541 shares of the medical instruments supplier’s stock worth $496,000 after purchasing an additional 7 shares during the last quarter. Finally, Northstar Group Inc. grew its stake in shares of Becton, Dickinson and by 0.3% in the second quarter. Northstar Group Inc. now owns 2,994 shares of the medical instruments supplier’s stock worth $584,000 after purchasing an additional 9 shares during the last quarter. 87.91% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This report was first reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this report on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The original version of this report can be viewed at https://theolympiareport.com/2017/11/23/traders-buy-shares-of-becton-dickinson-and-company-bdx-on-weakness.html.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.